As of Nov 19, 2026, 1 of 1 active firms rate DMAC a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
DMAC EPS & revenue forecast
EPS · NEXT QUARTER
$-0.19
Range $-0.19 – $-0.19 · 2 analysts · +0% YoY
Next period, 2 analysts expect DiaMedica Therapeutics Inc to earn $-0.19 a share (range $-0.19 – $-0.19), versus $-0.19 a year earlier. Full-year consensus is $-0.79, growing to $-0.75 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering DiaMedica Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DMAC.
#1
Chase Knickerbocker
Craig-Hallum · Rank #17
Buy
No targeton DMAC
Overall win rate
61%
+ Follow
#2
Josh Schimmer
Cantor Fitzgerald · Rank #132
Buy
$25.00+191.4% to target
Overall win rate
44%
+ Follow
#3
MC
Matthew Caufield
HC Wainwright & Co. · Rank #155
Buy
$12.00+39.9% to target
Overall win rate
49%
+ Follow
#4
TF
Thomas Flaten
Lake Street · Rank #306
Buy
$14.00+63.2% to target
Overall win rate
40%
+ Follow
#5
Joshua Schimmer
Cantor Fitzgerald
Buy
$25.00+191.4% to target
Coverage
—
+ Follow
DMAC stock forecast FAQ
What is DMAC's average 12-month price target?+
The 1 active firms with a live target average $12.00 for DiaMedica Therapeutics Inc over the next 12 months, ranging from a $12.00 high to a $12.00 low, as of Nov 19, 2026.
Is DMAC stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover DMAC?+
1 active firms have a recognized rating on DiaMedica Therapeutics Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering DMAC?+
Among analysts who currently cover DMAC, Chase Knickerbocker of Craig-Hallum has the strongest overall Quantellect track record (Rank #17). Their current call is Buy.
What is DiaMedica Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.19 per share (range $-0.19 – $-0.19) across 2 analysts. Full-year EPS is projected at $-0.79, rising to $-0.75 the following year.
How much revenue is DiaMedica Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading DMAC lately?+
As of Nov 19, 2026, 1 of 1 active firms rate DMAC a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DMAC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.